黏多糖贮积症酶替代治疗期间的脑磁共振表现
该研究对17例接受酶替代治疗的黏多糖贮积症儿童及年轻成人进行脑MRI,按9项参数评分并与临床严重程度比较。严重型MPS初始评分9–16分(均值12.2),衰减型2–11分(均值6.4);治疗后11/17(65%)患者改善或无变化,MPS I患者均有部分区域改善,1例MPS II患者中枢神经系统症状加重且MRI显示脑室扩大、脑萎缩及白质病变加重。
要点
- 严重型MPS初始MRI评分9–16分(均值12.2),衰减型2–11分(均值6.4)。
- 4例严重型MPS出现脑室扩大和脑萎缩,衰减型13例中仅2例出现。
- ERT后11/17(65%)患者MRI改善或无变化,无新发病灶。
核心结论
- 脑室扩大和脑萎缩可能作为预测黏多糖贮积症严重程度及中枢神经系统症状加重的有用标志物;酶替代治疗可改善MPS I的中枢神经系统影像,并对MPS II新发病灶有抑制作用。
研究设计与样本
- 对17例接受酶替代治疗的黏多糖贮积症儿童及年轻成人行脑MRI,由专科儿科医师根据临床症状和基因型分为衰减型或严重型,采用9项参数2分或3分量表评分,比较初始与随访MRI并归类为无变化、改善或加重,同时与临床改变比较。
关键影像表现/征象
- 严重型MPS中4例MRI显示脑室扩大和脑萎缩,衰减型MPS 13例中仅2例出现此类表现。
- 1例MPS II患者中枢神经系统症状加重,MRI显示脑室扩大、脑萎缩及白质病变较前加重。
- 随访期间未出现新发病灶。
诊断标准与关键数值
- 基于MRI的9项参数采用2分或3分量表评分,严重型MPS初始评分范围9–16分(均值12.2),衰减型MPS范围2–11分(均值6.4)。
- 治疗后影像归类为无变化、改善或加重,11/17(65%)患者表现为改善或无变化。
- 所有5例MPS I患者在某些区域出现改善。
临床应用与阅片要点
- 脑室扩大和脑萎缩可能作为预测黏多糖贮积症严重程度及中枢神经系统症状加重的有用标志物。
- 酶替代治疗可改善MPS I的中枢神经系统影像,并对MPS II新发病灶有抑制作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Although enzyme replacement therapy (ERT) is an effective treatment for mucopolysaccharidosis (MPS) types I, II, IVA and VI, its effectiveness in children with central nervous system (CNS) disorders is said to be poor because the blood-brain barrier cannot be penetrated by ERT drugs.
OBJECTIVE: To assess CNS involvement in mucopolysaccharidosis at the start of enzyme replacement therapy and to investigate the time course of ERT in the central nervous system.
MATERIALS AND METHODS: We performed brain MRI in 17 children and young adults who underwent ERT. The clinical severity was classified as attenuated or severe by a specialist pediatrician, based on the clinical symptoms and genotypes. At the start of ERT, we scored nine parameters using two- or three-point scales based on the severity of the disease revealed on MRI scans. After the start of ERT, we compared the initial and follow-up MRI scans, and classified the findings as no change, improved or worse. We then compared the results with the changes in clinical findings.
RESULTS: At the start of ERT, comparison of the clinical symptoms and image scores revealed differences between severe and attenuated mucopolysaccharidosis. The scores in patients with severe MPS ranged from 9 to 16 (mean 12.2); for patients with attenuated MPS, they ranged from 2 to 11 (mean 6.4). Images of the four patients with severe MPS showed ventricular dilation and brain atrophy. Such findings were made in only 2 of 13 patients with attenuated MPS. The results after the start of ERT showed that 11/17 (65%) patients manifested improvement or no change. All five patients with MPS I experienced improvement in some regions. There were no new lesions. One patient with MPS II experienced worsening of his CNS symptoms, and his MRI findings revealed more severe ventricular dilation, brain atrophy and white matter lesions.
CONCLUSION: Ventricular dilation and brain atrophy on imaging studies might represent useful markers in predicting the severity of mucopolysaccharidosis and worsening of CNS symptoms. Enzyme replacement therapy improves CNS images in MPS I and has an inhibitory effect on the occurrence of new lesions in MPS II.
引用
- Matsubara Y, Miyazaki O, Kosuga M, et al. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis. Pediatr Radiol. 2017. PMID: 28733853. doi:10.1007/s00247-017-3935-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。